Ernexa Therapeutics (NASDAQ:ERNA) Releases Quarterly Earnings Results, Beats Estimates By $1.95 EPS

Ernexa Therapeutics (NASDAQ:ERNA) issued its quarterly earnings results on Friday. The company reported ($1.89) EPS for the quarter, topping analysts’ consensus estimates of ($3.84) by $1.95, Zacks reports.

Ernexa Therapeutics Trading Up 2.2%

Shares of Ernexa Therapeutics stock traded up $0.04 during trading on Friday, reaching $1.87. 7,904 shares of the stock traded hands, compared to its average volume of 63,210. Ernexa Therapeutics has a 52-week low of $1.74 and a 52-week high of $46.11. The business has a fifty day simple moving average of $3.01 and a two-hundred day simple moving average of $6.91.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ERNA. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Thursday, October 15th. Wall Street Zen downgraded shares of Ernexa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $30.00.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.